BridgeBio Pharma Inc - Ordinary Shares
News
BridgeBio Pharma (NASDAQ:BBIO) Rating Reiterated by Bank of America
Ticker Report Bank of America restated their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO - Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $42.00 price...\n more…
BridgeBio Pharma (NASDAQ:BBIO) Rating Reiterated by Cantor Fitzgerald
Ticker Report BridgeBio Pharma (NASDAQ:BBIO - Get Free Report)s stock had its "overweight" rating reaffirmed by Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They presently have a $70.00...\n more…
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
Globe Newswire - Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in CAH patients - The gene therapy was well tolerated...\n more…
BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
Globe Newswire - Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements in all dosed patients indicating that BBP-812...\n more…
A Promising Pipeline Ready to Breakout at BridgeBio Pharma (BBIO)
TipRanks Financial Blog BridgeBio Pharma ($BBIO) is capturing attention with its unique approach to developing gene-based therapies for cancer and genetic-driven ailments. With a robust pi...\n more…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire PALO ALTO, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ( BridgeBio or the Company ), a commercial-stage biopharmaceutical company focused on genetic diseases...\n more…